Dave Levitan

The number of storms that leap from Category 1 to Category 3 or higher within 36 hours “more than doubled” over a 20-year period.

From effective rain-enhancing technology to a long, secretive history of trying to weaponize storms, there’s fertile ground for misinformation.

ASCO has issued a new clinical practice guideline on the use of systemic therapy for treatment of different types of thyroid cancer, a field that has changed substantially in recent years. 1

ASCO has issued an update to its living guideline on systemic therapies for patients with stage IV NSCLC without driver alterations. 1 The update, which includes a new recommendation regarding the PD-1 inhibitor retifanlimab-dlwr and chemotherapy, follows a recent full update to the guideline published in February 2026. 2

ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI. 1 The update is based on results from the TRIDENT-1 and Beamion LUNG-1 trials. 2,3